Search clinical trials for: Nivolumab and Ipilimumab and Combination for Metastatic Cancer

Total 1529 results

Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City

Completed

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Advanced Metastatic Cancer | Advanced Prostate Cancer

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Lung Cancer

Italy, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Recruiting

Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases (BC-BOMET)

Bone Metastases | Breast Cancer Metastatic

Italy
Yale University
Bristol-Myers Squibb

Completed

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Carcinoma, Non-Small-Cell Lung

United States
Yale University
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Small Cell Lung Cancer

United States
National University Hospital, Singapore

Recruiting

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Metastatic Solid Malignancies | Advance Solid Malignancies

Singapore
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
HUYABIO International, LLC.
Bristol-Myers Squibb

Recruiting

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma | Progressive Brain Metastasis

Spain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
Universitair Ziekenhuis Brussel

Not yet recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)

Recurrent Glioblastoma

Belgium
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
Fudan University
University College, London

Unknown

Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone

Prostate Cancer Metastatic

China
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb

Active, not recruiting

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

Metastatic Renal Cell Carcinoma

Canada, Australia
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb

Unknown

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2)

Brain Metastases

Italy
Bristol-Myers Squibb

Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)

Carcinoma, Renal Cell

United States, Italy, Brazil, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, France, Germany, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, Singapore, Spain, Switzerland, Turkey, United...
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Patrick Wen, MD
Bristol-Myers Squibb

Active, not recruiting

Surgical Nivolumab And Ipilimumab For Recurrent GBM

Glioblastoma | Glioblastoma Multiforme | GBM | Grade IV Astrocytoma

United States
Clinical Centre of Serbia

Completed

Comparison of Outcomes of Patients With Stage IV Chronic Limb-threatening Ischemia and Colorectal Cancer

Colorectal Carcinoma | Colorectal Carcinoma Metastatic in the Liver | Chronic Limb-Threatening Ischemia

Serbia
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
Baptist Health South Florida
Bristol-Myers Squibb; NovoCure Ltd.

Terminated

Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Recurrent Glioblastoma

United States
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Jason J. Luke, MD
Array BioPharma

Active, not recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Italian Network for Tumor Biotherapy Foundation
Bristol-Myers Squibb; Astex Pharmaceuticals, Inc.

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)

Melanoma | Non Small Cell Lung Cancer

Italy
Universitätsklinikum Köln
ZKS Köln

Withdrawn

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients (CERAD-IMMUNE)

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
Institut Claudius Regaud

Completed

TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (TICIMEL)

Melanoma

France
Consorzio Oncotech

Completed

Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) (GIM21)

Metastatic Breast Cancer

Italy
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
University of Pittsburgh
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Melanoma

United States
ARCAGY/ GINECO GROUP
Bristol-Myers Squibb

Active, not recruiting

COL Immunotherapy Before Radiochimio + Ipilimumab (COLIBRI)

Cervix Cancer

France
Bristol-Myers Squibb

Completed

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Melanoma

United States
Lung Cancer Group Cologne
Bristol-Myers Squibb

Completed

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell Lung

Germany
European Organisation for Research and Treatment...

Active, not recruiting

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE)

Gastric and Esophagogastric Junction Adenocarcinoma

United Kingdom, Italy, France, Spain, Germany, Czechia, Israel, Norway, Poland
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
HUYABIO International, LLC.

Completed

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

United States
University of Rochester

Active, not recruiting

Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Sarcoma

United States
University College, London
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Prostate Cancer

United Kingdom
Michael B. Atkins, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Metastatic Melanoma

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (MAPS2)

Mesothelioma

France
University Hospital Heidelberg

Unknown

Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP)

Cancer of Unknown Primary Site

Germany
Universita di Verona

Not yet recruiting

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)

HIV | HBV | Long COVID | NSCLC Stage IV | HCV

Italy
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
University of Zurich

Recruiting

Intrathecal Double Checkpoint Inhibition (IT-IO)

Melanoma Stage IV | Leptomeningeal Metastasis | Non-small Cell Lung Cancer Stage IV

Switzerland
National Cancer Institute (NCI)

Not yet recruiting

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Colorectal Cancer | Gastroesophageal Cancer

United States
Rennes University Hospital

Completed

Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY)

Advanced Non Small Cell Lung Cancer

France
Pfizer
Bristol-Myers Squibb

Completed

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MSS | RAS-mutant Colorectal Cancer

United States, Spain, Belgium, United Kingdom, Netherlands
AIO-Studien-gGmbH
Bristol-Myers Squibb

Active, not recruiting

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (TITAN-TCC)

Transitional Cell Carcinoma | Metastatic Cancer | Advanced Cancer

Germany, Austria
Universitair Ziekenhuis Brussel

Completed

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (ipniv)

Stage IV Skin Melanoma | Stage IIIC Skin Melanoma

Belgium
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb

Completed

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Melanoma

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Spain, France, Italy, Germany, United Kingdom, Belgium, Czechia, Austria

Search clinical trials for: Nivolumab and Ipilimumab and Combination for Metastatic Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations